From: Prognostic value of systemic immune-inflammation index in patients with gastric cancer
Characteristic | No. of patients (%) | Mean OS with 95% CI (months) | P valueb |
---|---|---|---|
Sex | 0.170 | ||
Man | 281 (63.3) | 54 (48–60) | |
Woman | 163 (36.7) | 61 (53–69) | |
Age (years) | 0.061 | ||
<60 | 249 (56.1) | 60 (53–66) | |
≥60 | 195 (43.9) | 53 (46–59) | |
Tumor location | 0.043 | ||
Upper stomach | 140 (31.5) | 48 (40–56) | |
Middle stomach | 137 (30.9) | 58 (50–67) | |
Lower stomach | 167 (37.6) | 62 (54–70) | |
Tumor size (cm) | <0.001 | ||
<5 | 221 (49.8) | 73 (66–80) | |
≥5 | 223 (50.2) | 40 (34–46) | |
Pathologic type | 0.330 | ||
Adenocarcinoma | 367 (82.7) | 57 (52–62) | |
Squamous carcinoma | 25 (5.6) | 50 (28–71) | |
Adenosquamous carcinoma | 3 (0.7) | 37 (18–57) | |
Ring cell carcinoma | 39 (8.8) | 53 (36–69) | |
Undifferentiated carcinoma | 10 (2.3) | 86 (39–133) | |
Borrmann classification | <0.001 | ||
1 | 30 (6.8) | 78 (55–102) | |
2 | 98 (22.1) | 76 (66–85) | |
3 | 259 (58.3) | 55 (49–61) | |
4 | 50 (11.3) | 20 (12–29) | |
5 | 7 (1.6) | 30 (3–55) | |
pTa | <0.001 | ||
1 | 53 (11.9) | 99 (87–110) | |
2 | 41 (9.2) | 89 (76–103) | |
3 | 175 (39.4) | 59 (52–65) | |
4 | 175 (39.4) | 34 (27–41) | |
pNa | <0.001 | ||
0 | 152 (34.2) | 92 (85–100) | |
1 | 185 (41.7) | 42 (36–48) | |
2 | 77 (17.3) | 34 (25–43) | |
3 | 30 (6.8) | 24 (12–37) | |
pMa | <0.001 | ||
0 | 337 (75.9) | 67 (63–73) | |
1 | 107 (24.1) | 21 (14–27) | |
TNM stagea | <0.001 | ||
I | 77 (17.3) | 101 (92–110) | |
II | 64 (14.4) | 79 (67–90) | |
III | 196 (44.1) | 52 (45–58) | |
IV | 107 (24.1) | 21 (14–27) | |
CEA (μg/L) | 0.023 | ||
<5 | 399 (89.9) | 59 (54–63) | |
≥5 | 45 (10.1) | 39 (26–53) | |
NLR | 0.510 | ||
<2.10 | 205 (46.2) | 65 (58–72) | |
≥2.10 | 239 (53.8) | 49 (43–56) | |
PLR | 0.201 | ||
<120 | 144 (32.4) | 67 (59–76) | |
≥120 | 300 (67.6) | 51 (46–57) | |
SII | <0.001 | ||
<660 | 283 (63.7) | 65 (59–71) | |
≥660 | 161 (36.3) | 42 (35–49) |